Several GLUT1 inhibitors, such as STF-31, WZB117, WZB27, WZB115, and BAY-876, have been developed and tested in preclinical models, and these compounds were found to inhibit glucose uptake and/or glycolysis, suppress cell proliferation, and induce apoptosis in multiple breast cancer cell lines [126,127,128]. This evidence concerns the gene SLC2A1 and breast carcinoma.